Norynta Bio
For US biotechs, drug developers and their supply teams · updated November 2026

Switching away from a China-linked CDMO or supplier? Get 3 verified options in 5 working days.

Each option comes with a dated evidence file you can hand to QA, your board or a contracting officer. Free for buyers.

Get my free shortlist

Or send your supplier list for a free exposure check

Why now

The list is due by 18 December 2026The BIOSECURE Act became law on 18 December 2025 (section 851 of the FY2026 NDAA). The Office of Management and Budget must publish its first list of biotechnology companies of concern within a year, then update it at least yearly.
The 1260H list feeds itBiotech entities on the Defense Department's 1260H list can be designated. Its June 2026 update added WuXi AppTec.
Qualifying a new site takes monthsRestrictions phase in through federal procurement rules after the list. Tech transfer, audits and comparability work take far longer than that.
Grants and contracts are at stakeCompanies with federal contracts or grants must avoid equipment and services from listed companies in that work. Investors and partners are asking now.

What you get, free

A shortlist in 5 working days: 3 qualified non-China options for your modality, scale and phase: biologics or small-molecule CDMO, API and key starting materials, oligonucleotides, peptides, bioprocess consumables and equipment, testing labs.

An evidence file for each option. Every fact has a source and a date:

Optional exposure check: send your current supplier list and we flag ownership ties to entities that are on, or may be added to, the relevant lists, as of the check date.

When OMB publishes the list we re-check every evidence file we have issued and tell you if anything changed.

How we're paid

You pay $0. If you buy, the supplier pays us a disclosed success fee after you have paid them. It is never added to your price, and every quote shows the supplier's price line by line. We never hold your money or the goods. Same checks for every supplier, no paid rankings.

Get my free shortlist

Questions

Will suppliers learn who we are?

Not until you agree to an introduction. Suppliers only see a description such as "a US biotech, antibody, phase 2".

Do you only cover CDMOs?

No: APIs and key starting materials, oligonucleotides, peptides, bioprocess consumables and equipment, and testing labs too.

Which countries do the options come from?

Wherever qualified capacity without China ties exists, often the US, EU, UK, Switzerland, Japan, Korea, Taiwan, India and Singapore.

Is this legal advice or a certification?

No. Evidence files are good-faith screening of public records and supplier documents. Your own qualification and legal review still apply. We never say a company is or will be on the list before OMB publishes it.

General information, not legal or regulatory advice. Sources: NDAA FY2026 section 851 (BIOSECURE Act, signed 18 December 2025); DoD Section 1260H list update, 8 June 2026; law-firm summaries from Baker McKenzie, Akin Gump and DLA Piper.